A Pilot Study of Home Treatment of Deep Vein Thrombosis With Subcutaneous Once-Daily Enoxaparin Plus Warfarin

Bishop, Beverly; Wilson, Andrew Gordon; Post, Douglas M.; Howard, Laureen; Ruehlen, Lawrence

doi:10.18553/jmcp.2006.12.1.70

Cited by 12 publications

(10 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…"Yükler ve zorluklar" alt boyutundan alınacak en düşük puan 9, en yüksek puan ise 63'dür. [39][40][41] Madde toplam puan korelasyon katsayısı ölçütü olarak 0.30'un üstü alındı. [41][42][43] Yarı test güvenir-lik için ölçeğin tümü ve alt boyutları için korelasyon katsayısı hesaplandı.…”

Section: Gereç Ve Yöntemlerunclassified

See 1 more Smart Citation

The validity and reliability of Turkish version of the Duke anticoagulation satisfaction scale

Yıldırım¹

2014

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

So nuç:Ölçeğin Türkçe formunun iç tutarlılık güvenirliği, içerik ve yapı geçerliliği açısından geçerli olduğu göste-rildi. Ölçek, pıhtı önler ilaç kullanan hastaların yaşadık-ları sorunları ve bakım gereksinimlerini değerlendirmek için sağlık profesyonellerinin kullanabileceği objektif bir araçtır.Anah tar söz cük ler: Pıhtı önler ilaçlar; hasta memnuniyeti; güve-nirlik ve geçerlik; ölçek; varfarin.Background: This study aims to evaluate the reliability and validity of the Turkish version of Duke Anticoagulation Satisfaction Scale (DASS) which was developed to assess the requirements and perceptions of patients receiving anticoagulant treatment.

show abstract

Section: Gereç Ve Yöntemlerunclassified

“…[34] Ancak bu ölçek birçok farklı araştırmada kullanılmıştır. [28,39,40] Özgün çalışmada ölçeğin iç tutarlığı 0.88 ve test-tekrar test korelasyonu 0.80'dir. Özgün ölçeğin alt boyutların iç tutarlılığı 0.78-0.91 arasında değişmektedir.…”

unclassified

The validity and reliability of Turkish version of the Duke anticoagulation satisfaction scale

Yıldırım¹

2014

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

show abstract

“…Regardless of the health care system, home treatment of DVT has been shown to reduce total cost of care by 40-60% [12,17,22,23]. Studies that have included quality-of-life measures have shown that patient prefer home treatment to hospitalization [4].…”

Section: Discussionmentioning

confidence: 99%

“…Observational studies have described the feasibility and cost-effectiveness of outpatient VTE treatment programs that were associated with good clinical outcomes [5][6][7][8][9][10][11][12][13][14][15][16][17][18], but these studies represent for the most part single-institution experiences encompassing patients with DVT in defined clinical settings. There is little multicenter published experience with the use of once-daily LMWH in a variety of usual practice settings that encompasses a wide spectrum of patients with DVT receiving home therapy including those with concurrent PE.…”

Section: Introductionmentioning

confidence: 99%

Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin

Hyers¹,

Spyropoulos

2007

J Thromb Thrombolysis

View full text Add to dashboard Cite

This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE). Short-term recurrence of venous thromboembolism (VTE) and safety were also evaluated. Patients with an objective diagnosis of DVT, with or without PE, were invited by their physician to participate in this study. Treatment was given according to the approved U.S. package inserts for tinzaparin (175 IU/kg SQ QD) and warfarin and the clinical judgment of the prescribing physician. Baseline patient history including demographic information and the results of tests to confirm the diagnosis of DVT, with or without PE, were collected. Follow-up information included the treatment setting in which each dose of tinzaparin was administered, medical training of the person administering tinzaparin doses, timing of initiation of warfarin with respect to that of tinzaparin, length of overlap of tinzaparin and warfarin therapy, and adverse experiences. A total of 334 patients were enrolled at 65 sites. Patients across a wide age (range 18-93 years old) and body weight (range 40-261 kg) were included. Overall, 27.3% of patients had cancer, and 50% of the overall study population reported more than one VTE risk factor. Mean duration of tinzaparin treatment was 7.61 days. Therapy at home was more common in suburban and rural settings than in urban settings. High proportions of patient, even among the small group with concurrent PE, were treated at home with self-injection. Severity of disease was the primary reason for hospitalization. Home treatment of DVT, with or without PE, with self administration of tinzaparin at 175 IU SQ once-daily was safe and resulted in an acceptably low rate of recurrent venous thromboembolism and adverse events. Home therapy in the usual practice setting should achieve substantial overall cost savings in the treatment of DVT.

show abstract

“…In RCT, patients are more likely to be regularly followed by visiting nurses 27 , have facilities to communicate with physicians responsible for the treatment and have the availability of fasttrack hospital evaluation in case of symptoms. Clinical pathways should be assured to minimise the risk of outpatient treatment 28 .…”

Section: Unresolved Issues and Concernsmentioning

confidence: 99%

Deep vein thrombosis: who still needs to be admitted?

Cei¹,

Cei²,

Mumoli³

2013

OA Case Reports

View full text Add to dashboard Cite

A Pilot Study of Home Treatment of Deep Vein Thrombosis With Subcutaneous Once-Daily Enoxaparin Plus Warfarin

Cited by 12 publications

References 26 publications

The validity and reliability of Turkish version of the Duke anticoagulation satisfaction scale

The validity and reliability of Turkish version of the Duke anticoagulation satisfaction scale

Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin

Deep vein thrombosis: who still needs to be admitted?

Contact Info

Product

Resources

About